Loading...
XSHE
300702
Market cap1.24bUSD
Oct 27, Last price  
25.44CNY
1D
0.16%
1Q
-2.23%
IPO
96.68%
Name

Zhejiang Tianyu Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
P/E
157.39
P/S
3.35
EPS
0.16
Div Yield, %
0.20%
Shrs. gr., 5y
1.32%
Rev. gr., 5y
4.50%
Revenues
2.63b
+4.10%
723,249,900777,349,724840,085,2681,082,338,8231,188,282,8091,466,956,3812,110,595,6802,587,395,7112,545,009,5272,666,678,4712,527,270,1112,630,808,243
Net income
56m
+104.45%
33,588,40024,139,82550,354,815122,337,689100,182,148163,661,953585,725,746667,060,796204,676,095027,359,25755,935,067
CFO
345m
P
39,731,80080,438,31614,751,417164,739,55688,516,86978,572,392427,836,939622,180,52000-43,904,902344,638,322
Dividend
Jun 06, 20240.05 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical intermediates and APIs in China and internationally. The company offers pharmaceutical intermediates and APIs of cardiovascular, anti-diabetic, anti-atherosclerosis, anticoagulant, and anti-asthmatic series. It also provides fine chemicals and CMO services. The company was founded in 1993 and is based in Taizhou, China.
IPO date
Sep 19, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT